Cargando…

Distribution of Clostridium Difficile Ribotypes in Macedonian Patients and their Antimicrobial Susceptibility

BACKGROUND: Clostridium difficile is a major nosocomial pathogen. In Europe, this bacterium is mostly characterised by PCR ribotyping. Most of the Clostridium difficile infections (CDI) are treated with vancomycin or metronidazole, although prolonged antibiotic use is considered as one of the main r...

Descripción completa

Detalles Bibliográficos
Autores principales: Mihajlov, Kiril, Andreska, Aneta, Ristovska, Nadica, Grdanoska, Tatjana, Trajkovska-Dokic, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Republic of Macedonia 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684425/
https://www.ncbi.nlm.nih.gov/pubmed/31406525
http://dx.doi.org/10.3889/oamjms.2019.482
_version_ 1783442245092900864
author Mihajlov, Kiril
Andreska, Aneta
Ristovska, Nadica
Grdanoska, Tatjana
Trajkovska-Dokic, Elena
author_facet Mihajlov, Kiril
Andreska, Aneta
Ristovska, Nadica
Grdanoska, Tatjana
Trajkovska-Dokic, Elena
author_sort Mihajlov, Kiril
collection PubMed
description BACKGROUND: Clostridium difficile is a major nosocomial pathogen. In Europe, this bacterium is mostly characterised by PCR ribotyping. Most of the Clostridium difficile infections (CDI) are treated with vancomycin or metronidazole, although prolonged antibiotic use is considered as one of the main risk factors for CDI. AIM: This study aimed to detect the presence of various C. difficile ribotypes in hospitalised patients and to investigate their toxigenicity and antibiotic susceptibility. MATERIAL AND METHODS: All stool samples obtained from each patient were inoculated on Columbia blood agar and cycloserine cefoxitine fructose agar (CCFA) for isolation of C. difficile. Glutamate dehydrogenase and toxins A and B were investigated by immunochromatographic tests. Final confirmation of the isolates was performed by Vitek 2 and MALDI-TOF. A total of 21 isolates were collected for further investigation. PCR ribotyping was performed as described by Janezic and Rupnik. PCR ribotype profiles were analysed using software (Bionumerics, Applied Maths). Antibiotic susceptibility was determined by E-tests for metronidazole, vancomycin, tetracycline, clindamycin, erythromycin, imipenem, ciprofloxacin and moxifloxacin. RESULTS: About 48% of C. difficile isolates belonged to ribotype 001/072. So, this ribotype was the most common ribotype in this study. The remaining 52% of C. difficile isolates consisted of 10 different ribotypes: 017, SLO 160, SLO 187, SLO 120, 255/258, 014/020, 046, 002, 070 and 027. Furthermore, 20 (95.2 %) out of 21 isolates of C. difficile were toxigenic. Toxins A and B were detected simultaneously in 90.5 % of C. difficile isolates. Two isolates from the ribotype 017 were toxin B positive only. Treatments with any of the following antimicrobials: clindamycin, erythromycin, ciprofloxacin and moxifloxacin (as well as many other antibiotics), could be a risk factor for CDI due to the high resistance of the strains in this study. About 90% of the strains from the most common ribotype 001/072 have MICs for clindamycin and erythromycin > 256 µg/ml. CONCLUSION: All strains isolated are highly resistant to ciprofloxacin. All strains were susceptible to vancomycin (median MIC was 0.63 µg/ml) and metronidazole (median MIC was 0.084 µg/ml), so these two antimicrobials remain optimal treatment option for CDI.
format Online
Article
Text
id pubmed-6684425
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Republic of Macedonia
record_format MEDLINE/PubMed
spelling pubmed-66844252019-08-12 Distribution of Clostridium Difficile Ribotypes in Macedonian Patients and their Antimicrobial Susceptibility Mihajlov, Kiril Andreska, Aneta Ristovska, Nadica Grdanoska, Tatjana Trajkovska-Dokic, Elena Open Access Maced J Med Sci Basic Science BACKGROUND: Clostridium difficile is a major nosocomial pathogen. In Europe, this bacterium is mostly characterised by PCR ribotyping. Most of the Clostridium difficile infections (CDI) are treated with vancomycin or metronidazole, although prolonged antibiotic use is considered as one of the main risk factors for CDI. AIM: This study aimed to detect the presence of various C. difficile ribotypes in hospitalised patients and to investigate their toxigenicity and antibiotic susceptibility. MATERIAL AND METHODS: All stool samples obtained from each patient were inoculated on Columbia blood agar and cycloserine cefoxitine fructose agar (CCFA) for isolation of C. difficile. Glutamate dehydrogenase and toxins A and B were investigated by immunochromatographic tests. Final confirmation of the isolates was performed by Vitek 2 and MALDI-TOF. A total of 21 isolates were collected for further investigation. PCR ribotyping was performed as described by Janezic and Rupnik. PCR ribotype profiles were analysed using software (Bionumerics, Applied Maths). Antibiotic susceptibility was determined by E-tests for metronidazole, vancomycin, tetracycline, clindamycin, erythromycin, imipenem, ciprofloxacin and moxifloxacin. RESULTS: About 48% of C. difficile isolates belonged to ribotype 001/072. So, this ribotype was the most common ribotype in this study. The remaining 52% of C. difficile isolates consisted of 10 different ribotypes: 017, SLO 160, SLO 187, SLO 120, 255/258, 014/020, 046, 002, 070 and 027. Furthermore, 20 (95.2 %) out of 21 isolates of C. difficile were toxigenic. Toxins A and B were detected simultaneously in 90.5 % of C. difficile isolates. Two isolates from the ribotype 017 were toxin B positive only. Treatments with any of the following antimicrobials: clindamycin, erythromycin, ciprofloxacin and moxifloxacin (as well as many other antibiotics), could be a risk factor for CDI due to the high resistance of the strains in this study. About 90% of the strains from the most common ribotype 001/072 have MICs for clindamycin and erythromycin > 256 µg/ml. CONCLUSION: All strains isolated are highly resistant to ciprofloxacin. All strains were susceptible to vancomycin (median MIC was 0.63 µg/ml) and metronidazole (median MIC was 0.084 µg/ml), so these two antimicrobials remain optimal treatment option for CDI. Republic of Macedonia 2019-06-30 /pmc/articles/PMC6684425/ /pubmed/31406525 http://dx.doi.org/10.3889/oamjms.2019.482 Text en Copyright: © 2019 Kiril Mihajlov, Aneta Andreska, Nadica Ristovska, Tatjana Grdanoska, Elena Trajkovska-Dokic. http://creativecommons.org/licenses/CC BY-NC/4.0 This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
spellingShingle Basic Science
Mihajlov, Kiril
Andreska, Aneta
Ristovska, Nadica
Grdanoska, Tatjana
Trajkovska-Dokic, Elena
Distribution of Clostridium Difficile Ribotypes in Macedonian Patients and their Antimicrobial Susceptibility
title Distribution of Clostridium Difficile Ribotypes in Macedonian Patients and their Antimicrobial Susceptibility
title_full Distribution of Clostridium Difficile Ribotypes in Macedonian Patients and their Antimicrobial Susceptibility
title_fullStr Distribution of Clostridium Difficile Ribotypes in Macedonian Patients and their Antimicrobial Susceptibility
title_full_unstemmed Distribution of Clostridium Difficile Ribotypes in Macedonian Patients and their Antimicrobial Susceptibility
title_short Distribution of Clostridium Difficile Ribotypes in Macedonian Patients and their Antimicrobial Susceptibility
title_sort distribution of clostridium difficile ribotypes in macedonian patients and their antimicrobial susceptibility
topic Basic Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6684425/
https://www.ncbi.nlm.nih.gov/pubmed/31406525
http://dx.doi.org/10.3889/oamjms.2019.482
work_keys_str_mv AT mihajlovkiril distributionofclostridiumdifficileribotypesinmacedonianpatientsandtheirantimicrobialsusceptibility
AT andreskaaneta distributionofclostridiumdifficileribotypesinmacedonianpatientsandtheirantimicrobialsusceptibility
AT ristovskanadica distributionofclostridiumdifficileribotypesinmacedonianpatientsandtheirantimicrobialsusceptibility
AT grdanoskatatjana distributionofclostridiumdifficileribotypesinmacedonianpatientsandtheirantimicrobialsusceptibility
AT trajkovskadokicelena distributionofclostridiumdifficileribotypesinmacedonianpatientsandtheirantimicrobialsusceptibility